Sarepta Therapeutics, Inc. (SRPT) — Financial statements
Income statement, balance sheet, and cash flow for Sarepta Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 2,198↑15.6% | 1,902↑53.0% | 1,243↑33.3% | 933↑32.9% | 702 | |
| Cost of Revenue | 882↑176.2% | 319↑112.2% | 150↑7.4% | 140↑44.2% | 97 | |
| Gross Profit | 1,317↓16.8% | 1,583↑44.8% | 1,093↑37.8% | 793↑31.1% | 605 | |
| Operating Expenses | ||||||
| R&D Expenses | 1,522↑89.2% | 805↓8.3% | 877↑0.0% | 877↑13.7% | 771 | |
| General & Administrative Expenses | 479↓14.1% | 558↑15.8% | 482↑6.7% | 451↑59.7% | 283 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 479↓14.1% | 558↑15.8% | 482↑6.7% | 451↑59.7% | 283 | |
| Other Expenses | -26↓1201.7% | 2↑54.3% | 2↑118.3% | 0.71↓93.3% | 11 | |
| Operating Expenses | 1,975↑44.7% | 1,365↑0.3% | 1,361↑2.4% | 1,329↑24.9% | 1,065 | |
| Total Costs & Expenses | 2,856↑69.6% | 1,684↑11.4% | 1,511↑2.9% | 1,469↑26.5% | 1,162 | |
| Operating Results | ||||||
| Operating Income | -658↓401.6% | 218↑181.4% | -268↑50.1% | -536↓16.6% | -460 | |
| Depreciation & Amortization | 45↑18.0% | 38↓15.0% | 44↑6.1% | 42↑10.1% | 38 | |
| EBITDA | -648↓304.5% | 317↑169.8% | -454↑23.7% | -595↓87.4% | -317 | |
| EBIT | -692↓348.1% | 279↑156.0% | -498↑21.8% | -637↓79.1% | -355 | |
| Interest & Other Income | ||||||
| Net Interest Income | 10↓81.6% | 53↓16.5% | 64↑350.6% | -26↑59.5% | -63 | |
| Interest Income | 20↓72.7% | 72↓16.5% | 86↑210.1% | 28↑5325.2% | 0.51 | |
| Interest Expense | 10↓47.1% | 18↓16.4% | 22↓58.7% | 53↓16.2% | 64 | |
| Non-Operating Income | 35↑156.8% | -61↓126.5% | 230↑129.1% | 101↑196.4% | -104 | |
| Other Income / Expenses | -44↓204.1% | 43↑116.9% | -252↓64.1% | -154↓477.2% | 41 | |
| Income Before Tax | -702↓369.3% | 261↑150.1% | -520↑24.6% | -690↓64.7% | -419 | |
| Income Tax Expense | 11↓56.2% | 26↑60.8% | 16↑17.4% | 14↑8150.6% | -0.17 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -713↓403.3% | 235↑143.9% | -536↑23.8% | -703↓68.0% | -419 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -713↓403.3% | 235↑143.9% | -536↑23.8% | -703↓68.0% | -419 | |
| Bottom-Line Net Income | -713↓403.3% | 235↑143.9% | -536↑23.8% | -703↓68.0% | -419 | |
| EPS (Basic) | -7.13↓388.7% | 2.47↑142.6% | -5.80↑27.8% | -8.03↓55.9% | -5.15 | |
| EPS (Diluted) | -7.13↓404.7% | 2.34↑140.3% | -5.80↑27.8% | -8.03↓55.9% | -5.15 | |
| Weighted Average Shares | 105↑10.2% | 95↑2.9% | 92↑5.5% | 88↑7.7% | 81 | |
| Weighted Average Diluted Shares | 105↓2.9% | 108↑16.8% | 92↑5.5% | 88↑7.7% | 81 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.